Clinical trials recruiting for HER2 Negative Breast Carcinoma
15
Recruiting trials
47
US states with sites
24
Countries
7%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Cyclophosphamide | 2 |
| Letrozole | 2 |
| Abemaciclib | 1 |
| Anastrozole | 1 |
| Aromatase Inhibition Therapy | 1 |
| BCNU | 1 |
| Coriolus Versicolor Extract | 1 |
| Datopotamab deruxtecan | 1 |
| Docetaxel | 1 |
| Doxorubicin | 1 |
| Durvalumab | 1 |
| Exemestane | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 7 |
| California | 5 |
| Florida | 5 |
| Massachusetts | 5 |
| North Carolina | 5 |
| Ohio | 5 |
| New Jersey | 4 |
| Arkansas | 3 |
| Connecticut | 3 |
| Georgia | 3 |
| Illinois | 3 |
| Iowa | 3 |
Top cities
New York, New York 6Columbus, Ohio 5Boston, Massachusetts 4San Francisco, California 4Beverly Hills, California 3Kansas City, Missouri 3Minneapolis, Minnesota 3Peoria, Illinois 3Vallejo, California 3Aberdeen, Maryland 2
Self-screener
Recruiting trials
- A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
- Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
- Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
- Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
- Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
- Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Related conditions
Trials recruiting for HER2 Negative Breast Carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239HER2-negative Breast Cancer 57Anatomic Stage II Breast Cancer AJCC v8 35Anatomic Stage III Breast Cancer AJCC v8 39Metastatic breast cancer 131Hormone Receptor Positive Breast Carcinoma 13Anatomic Stage I Breast Cancer AJCC v8 30Metastatic Triple-Negative Breast Carcinoma 18Hormone-receptor-positive Breast Cancer 24Estrogen Receptor-Positive Breast Carcinoma 5
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for HER2 Negative Breast Carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.